By Colin Kellaher
Aura Biosciences has named Anthony Gibney as the clinical-stage biotechnology company's new chief financial and business officer.
Aura on Thursday said Gibney, 54 years old, joined the Boston company as a senior finance and strategy adviser in March.
The company said Gibney will receive an annual base salary of $525,000 and an annual bonus with a target of 45% of his base pay.
Amy Elazzouzi, Aura's senior vice president of finance, has been serving as interim chief financial officer since Julie Feder left the company last year. Aura said Elazzouzi will no longer serve as its principal financial officer but will remain principal accounting officer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 15, 2025 07:55 ET (11:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.